Cantargia
Manufacturing · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Scheelevägen 27, Lund, Skane, 223 63, Sw...Phone Number
+46 462756260Website
www.cantargia.comRevenue
-Stock Symbol
CANTAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Cantargia
Cantargia AB, a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases.Explore more
Cantargia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cantargia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Cantargia
Earning: See what the market has to say on Cantargia recently announced quarterly report
Cantargia, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Cantargia has recently received funding, and reach out quickly before it becomes old news!
Check out if Cantargia is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Cantargia launches new products
Click to see if Cantargia had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Cantargia has new funding data
Recommended Actions
Find VP level buyers at Cantargia
Find more new buyers
Company Profile Activity
Activity Insights
Cantargia is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cantargia is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cantargia.
Cantargia financials insights
Gather financial insights about Cantargia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Debt
$5.2M
Cantargia Tech Stack
A closer look at the technologies used by Cantargia
Most Recent Scoops
Earnings
Cantargia has reported revenues of SEK 0.6 million for the first six months of 2026, all derived from the Otsuka collaboration, with operating expenses of SEK 73.3 million resulting in an operating loss of SEK 72.7 million. After positive net financial items of SEK 6.9 million, the net loss for the period was SEK 65.8 million, corresponding to a loss per share of SEK 0.26.
Earnings, Accounting, Financial Reporting, Finance
Earnings
Cantargia has reported revenues of SEK 100,000 for Q2 2026, with operating expenses of SEK 35.9 million resulting in an operating loss of SEK 35.8 million. After positive net financial items of SEK 3 million, the net loss for the period was SEK 32.8 million, corresponding to a loss per share of SEK 0.13.
Earnings, Finance
Project
Cantargia has reported that all five evaluable patients in the high-risk MDS cohort of its nadunolimab study achieved complete remission at the most recent data cut, with a sixth patient still pending evaluation.
Medical Research, Clinical Operations
Earnings
Cantargia has reported that operating expenses decreased 9% year-over-year in Q2 2026 to SEK 35.9 million from SEK 39.5 million in Q2 2025, and decreased 13% year-to-date to SEK 73.3 million from SEK 84.5 million in H1 2025, reflecting lower R&D activity following the CAN10 divestment and reduced nadunolimab activities ahead of the planned combination study with daraxonrasib.
Earnings, Finance
Project
Medical Research, Pharmaceuticals
Cantargia News & Media
Cantargia Secures SEK 50 Million Financing to Extend Financial Runway - TipRanks.com
An update from Cantargia AB ( ($SE:CANTA) ) is now available. Cantargia AB has secured a SEK 50 million loan agreement with Fenja Capital II A/S, extending its fina...Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer
Cantargia announced that its Chief Operating Officer , Liselotte Larsson has resigned and will continue her career outside Cantargia. She will depart her role by mid-October, 2024. Liselotte Larsson...Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023
LUND, Sweden, April 4, 2023 /PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day focusing on new clinical results and biomarker data for its lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), in pancreatic cancer (PDAC)...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cantargia
Sign Up For FreeTo access detailed company insights
Cantargia AB, a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases.... Read More
